Comparison of Outcomes After Cardioversion or Atrial Fibrillation Ablation in Patients With Differing Periprocedural Anticoagulation Regimens

Canadian Journal of Cardiology

Volumn 30, Issue 12, 2014, Pages 1541-1546

  Kochhäuser, Simon ^a   Khaykin, Yaariv ^a   Beardsall, Jessica ^a   Juta, Rasna ^a   Hache, Philip ^a   Trought, Kathleen ^a   Lenton Brym, Talia ^a   Tsang, Bernice ^a   Pantano, Alfredo ^a   Beardsall, Marianne ^a   Wulffhart, Zaev ^a   Verma, Atul ^a  

^a SOUTHLAKE REGIONAL HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DABIGATRAN; RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT;

AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CARDIOVERSION; CEREBROVASCULAR ACCIDENT; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PULMONARY VEIN ISOLATION; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; ATRIAL FIBRILLATION; CANADA; CATHETER ABLATION; COMPLICATION; FOLLOW UP; INCIDENCE; MIDDLE AGED; PATHOPHYSIOLOGY; PROCEDURES; RETROSPECTIVE STUDY; STROKE;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; CATHETER ABLATION; ELECTRIC COUNTERSHOCK; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; ONTARIO; RETROSPECTIVE STUDIES; STROKE; TREATMENT OUTCOME;

EID: 84919762361     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2014.09.018     Document Type: Article

References (24)

1. Healey J.S., Parkash R., Pollak T., Tsang T., Dorian P. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: etiology and initial investigations. Can J Cardiol 2011, 27:31-37.
2. Verma A., Macle L., Cox J., Skanes A.C. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: catheter ablation for atrial fibrillation/atrial flutter. Can J Cardiol 2011, 27:60-66.
3. Cairns J.A., Connolly S., McMurtry S., Stephenson M., Talajic M. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter. Can J Cardiol 2011, 27:74-90.
4. Verma A, Mitchell LB, Macle L, etal. 2014 Focused update of the Canadian Cardiovascular Society guidelines for the management of atrial fibrillation. 2014;30:1114-30.
5. Naccarelli G.V., Johnston S.S., Lin J., Patel P.P., Schulman K.L. Cost burden of cardiovascular hospitalization and mortality in ATHENA-like patients with atrial fibrillation/atrial flutter in the United States. Clin Cardiol 2010, 33:270-279.
6. Santangeli P., Di Biase L., Sanchez J.E., Horton R., Natale A. Atrial fibrillation ablation without interruption of anticoagulation. Cardiol Res Pract 2011, 2011:837841.
7. Camm A.J., Lip G.Y., De Caterina R., et al. 2012 Focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012, 33:2719-2747.
8. Skanes A.C., Healey J.S., Cairns J.A., et al. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol 2012, 28:125-136.
9. Mardigyan V., Verma A., Birnie D., et al. Anticoagulation management pre- and post atrial fibrillation ablation: a survey of Canadian centres. Can J Cardiol 2013, 29:219-223.
10. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J 2010, 159:340-347.e1. ROCKET AF Study Investigators.
11. Nagarakanti R., Ezekowitz M.D., Oldgren J., et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation 2011, 123:131-136.
12. Piccini J.P., Stevens S.R., Lokhnygina Y., et al. Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. JAm Coll Cardiol 2013, 61:1998-2006.
13. Yadlapati A., Groh C., Passman R. Safety of short-term use of dabigatran or rivaroxaban for direct-current cardioversion in patients with atrial fibrillation and atrial flutter. Am J Cardiol 2014, 113:1362-1363.
14. Page S.P., Siddiqui M.S., Finlay M., et al. Catheter ablation for atrial fibrillation on uninterrupted warfarin: can it be done without echo guidance?. JCardiovasc Electrophysiol 2011, 22:265-270.
15. Gautam S., John R.M., Stevenson W.G., et al. Effect of therapeutic INR on activated clotting times, heparin dosage, and bleeding risk during ablation of atrial fibrillation. JCardiovasc Electrophysiol 2011, 22:248-254.
16. Gopinath D., Lewis W.R., Di Biase L., Natale A. Pulmonary vein antrum isolation for atrial fibrillation on therapeutic coumadin: special considerations. JCardiovasc Electrophysiol 2011, 22:236-239.
17. Hakalahti A., Uusimaa P., Ylitalo K., Raatikainen M.J. Catheter ablation of atrial fibrillation in patients with therapeutic oral anticoagulation treatment. Europace 2011, 13:640-645.
18. Di Biase L., Burkhardt D., Santangeli P., et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the "COMPARE" randomized trial. Circulation 2014, 129:2638-2644.
19. Lakkireddy D., Reddy Y.M., Di Biase L., et al. Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. JAm Coll Cardiol 2012, 59:1168-1174.
20. Shurrab M., Morillo C.A., Schulman S., et al. Safety and efficacy of dabigatran compared with warfarin for patients undergoing radiofrequency catheter ablation of atrial fibrillation: a meta-analysis. Can J Cardiol 2013, 29:1203-1210.
21. Bin Abdulhak A.A., Khan A.R., Tleyjeh I.M., et al. Safety and efficacy of interrupted dabigatran for peri-procedural anticoagulation in catheter ablation of atrial fibrillation: a systematic review and meta-analysis. Europace 2013, 15:1412-1420.
22. Lakkireddy D., Reddy Y.M., Di Biase L., et al. Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. JAm Coll Cardiol 2014, 63:982-988.
23. Stepanyan G., Badhwar N., Lee R.J., et al. Safety of new oral anticoagulants for patients undergoing atrial fibrillation ablation. JInterv Card Electrophysiol 2014, 40:33-38.
24. Providencia R., Marijon E., Albenque J.P., et al. Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation. Europace 2014, 16:1137-1144.